Technical and immunologic progress in simultaneous pancreas-kidney transplantation

被引:15
作者
Kaufman, DB
Leventhal, JR
Gallon, LG
Parker, MA
Elliott, MD
Gheorghiade, M
Koffron, AJ
Fryer, JP
Abecassis, MM
Stuart, FP
机构
[1] Northwestern Univ, Sch Med, Dept Surg, Div Transplantat, Chicago, IL 60611 USA
[2] Northwestern Univ, Sch Med, Dept Med, Div Transplantat, Chicago, IL 60611 USA
[3] Northwestern Univ, Sch Med, Dept Med, Div Nephrol, Chicago, IL 60611 USA
[4] Northwestern Univ, Sch Med, Dept Surg, Div Nephrol, Chicago, IL 60611 USA
[5] Northwestern Univ, Sch Med, Dept Surg, Div Cardiol, Chicago, IL 60611 USA
[6] Northwestern Univ, Sch Med, Dept Med, Div Cardiol, Chicago, IL 60611 USA
关键词
D O I
10.1067/msy.2002.127547
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. During the past few year's the use of new immunosuppressants and refinements in surgical technique of simultaneous pancreas-kidney (SPK) transplantation have resulted in markedly improved outcomes. This is a retrospective study of 208 SPK transplants performed at Northwestern University, demonstrating the advances made at a single center that are reflective of the field at large. Methods. An 8.5-year time span was split into 4 distinct eras marking sequential changes in immunosuppression and surgical technique that ensued. SPK transplant outcomes of patient and graft survival and rejection rates were compared. Also examined were end points related to the changing risk profile of the recipients, as well as quality of allograft function and rates of rehospitalizations. Results. Recipients receiving tacrolimus/mycophenolate mofetil-based immunosuppression had patient, kidney, and pancreas survival rates significantly higher than those of earlier cohorts. The elimination of corticosteroids did not reduce survival rates or increase reflection risk. The use of pancreatic exocrine enteric drainage technique over bladder drainage reduced rehospitalizations. Conclusions. Advances in immunosuppression management combined with technical refinements have made SPK transplantation a safer and more effective treatment option for the diabetic, uremic Patient.
引用
收藏
页码:545 / 553
页数:9
相关论文
共 22 条
[1]  
*AM DIAB ASS, 2000, DIABETES CARE S1, V23, pS85
[2]  
Benedetti E, 1996, J AM COLL SURGEONS, V183, P307
[3]   Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients [J].
Bruce, DS ;
Sollinger, HW ;
Humar, A ;
Sutherland, DER ;
Light, JA ;
Kaufman, DB ;
Alloway, RR ;
Lo, A ;
Stratta, RJ .
TRANSPLANTATION, 2001, 72 (10) :1637-1643
[4]  
ELKHAMMAS EA, 1997, TRANSPLANT REV, V11, P1
[5]  
Gruessner A, 1994, Clin Transpl, P47
[6]  
Gruessner A C, 2000, Clin Transpl, P45
[7]  
KAPLAN EL, 1958, J AM STAT ASSOC, V53, P163
[8]   A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation - Comparison of two maintenance immunosuppression protocols: Tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus [J].
Kaufman, DB ;
Leventhal, JR ;
Koffron, AJ ;
Gallon, LG ;
Parker, MA ;
Fryer, JP ;
Abecassis, MM ;
Stuart, FP .
TRANSPLANTATION, 2002, 73 (02) :169-177
[9]   Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation [J].
Kaufman, DB ;
Leventhal, JR ;
Gallon, LG ;
Parker, MA ;
Koffron, AJ ;
Fryer, JP ;
Abecassis, MM ;
Stuart, FP .
TRANSPLANTATION, 2001, 72 (12) :1940-1945
[10]   Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation - Initial experience in 50 consecutive cases [J].
Kaufman, DB ;
Leventhal, JR ;
Stuart, J ;
Abecassis, MM ;
Fryer, JP ;
Stuart, FP .
TRANSPLANTATION, 1999, 67 (04) :586-593